NASDAQ: ONCYOncolytics Biotech Inc Stock
$0.59+0.02 (+3.51%)
Updated Apr 29, 2025
ONCY Price
$0.59
Fair Value Price
N/A
Market Cap
$47.37M
52 Week Low
$0.47
52 Week High
$1.53
P/E
-2.05x
P/B
11.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.02M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.37
Operating Cash Flow
-$19M
Beta
0.92
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ONCY Overview
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ONCY's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ONCY
Ranked#354 of 462
Ranked#354 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important ONCY news, forecast changes, insider trades & much more!
ONCY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ONCY is poor value based on its book value relative to its share price (11.24x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
ONCY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ONCY due diligence checks available for Premium users.
Valuation
ONCY fair value
Fair Value of ONCY stock based on Discounted Cash Flow (DCF)
Price
$0.59
Fair Value
$0.34
Overvalued by
71.74%
ONCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ONCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.05x
Industry
-158.75x
Market
29.19x
ONCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.24x
Industry
4.37x
ONCY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONCY's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.6M
Profit Margin
0%
ONCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.0M
Liabilities
$9.9M
Debt to equity
2.37
ONCY's short-term assets ($13.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCY's short-term assets ($13.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ONCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
-$4.2k
Financing
$2.3M
ONCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCY vs Biotech Stocks
Oncolytics Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.